Download PDF
Z Gastroenterol 2007; 45(10): 1085-1088
DOI: 10.1055/s-2007-963473
Kommentiertes Referat

© Georg Thieme Verlag KG Stuttgart · New York

Proteaseinhibitoren in der Therapie der chronischen Hepatitis C

Protease Inhibitors in the Treatment of Chronic Hepatitis CJ. Vermehren, C. Sarrazin
  • 1Medizinische Klinik I, Klinikum der J.-W.-Goethe-Universität Frankfurt
Further Information

Publication History

Publication Date:
09 October 2007 (online)

Also available at
    Permissions and Reprints

Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Kauffman R, Alam J, Jansen PLM. Rapid Decline of Viral RNA in Hepatitiis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study. Gastroenterology 2006; 131: 997 - 1002

Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Hui-May C, Purdy S, Jansen PLM, Zeuzem S. Antiviral Activity of Telaprevir (VX-950) and Peginterferon Alfa-2a in Patients with Hepatitis C. Hepatology 2007; in press

Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S. SCH 503 034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon Alfa-2b for Genotype 1 Nonresponders. Gastroenterology 2007; 132: 1270 - 1278

Prof. Dr. med. Christoph Sarrazin

Medizinische Klinik I, Zentrum der Inneren Medizin, Klinikum der J.-W.-Goethe-Universität

Theodor-Stern-Kai 7

60590 Frankfurt am Main

Phone: ++ 49/69-63 01 51 22

Fax: ++ 49/69-63 01 64 48

Email: sarrazin@em.uni-frankfurt.de